FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

Published Date: 16 May 2026

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

Read Full News

Latest News

OA Tied to Arthritis AE Risk in ICI-Treated Patients

In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.

Stem Cell Transplant Linked to Longer Survival in CMML

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Gatekeeping May Reduce Pediatric Cancer Trial Participation

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

AI Framework Helps Classify Renal Tumors, Predict Outcomes

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Dual Checkpoint Blockade Boosts Breast Cancer pCR

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

Todays Updates

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

Inconclusive BRCA Results Linked to Higher BC Risk

A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.

Todays Updates

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

Inconclusive BRCA Results Linked to Higher BC Risk

A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.

Latest News

In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

News All Time

Stem Cell Transplant Associated With Better PFS in NKTCL

Researchers aim to evaluate the effectiveness of ASCT as consolidation therapy for patients with advanced-stage natural killer/T-cell lymphoma who have attained their first complete remission.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events

A lung cancer trial was stopped early due to a high rate of fatal adverse events with the addition of thoracic radiotherapy to standard maintenance immunotherapy.

Smoldering Myeloma: The Treatment Issue Is Getting Trickier

An FDA approval, striking CAR T data, and a field that can't agree on what to do next. Experts weigh in on the most contentious question in myeloma.

Quizartinib Benefit in AML Limited to FLT3-Mutated Subgroup

A recent trial assesses whether the addition of quizartinib following intensive chemotherapy improves survival outcomes in older patients with previously untreated AML.

FDA Approves New ROS1 Inhibitor for NSCLC

The newly approved inhibitor is for patients who previously received another drug of the same class.

Patients With Early-Onset Cancer Unaware of Infertility Risk

Many patients with early-onset cancer say they were never told that treatments could affect their fertility.

Virtual Help Doubles Cancer Patients’ Smoking Quit Rate

Programs offering telehealth counseling and nicotine replacement products should be part of routine oncology care, researchers say.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Researchers evaluate minimal residual disease status in 128 adults with relapsed or refractory follicular lymphoma treated with epcoritamab.

Germline Profiling May Improve Risk Stratification in t-MNs

A new study explores whether germline profiling could refine the subclassification and prognosis of therapy-related myeloid neoplasms beyond treatment history alone.

Body Clock Genes Tied to Prostate Radiotherapy Toxicity

Could timing prostate cancer radiotherapy according to patients’ circadian rhythm genes reduce the risk for late side effects?

Gedatolisib Combo Approved for Advanced Breast Cancer

Progression-free survival with the multitarget PAM inhibitor approaches 10 months after anti-CDK4/6 and aromatase inhibitor failure.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

In a small single-center study, 1-year survival is 100% among carefully selected patients who undergo bilateral lung transplantation for stage IV disease confined to the lungs.

MGRS Relapse-Free Survival Better With Maintenance Therapy

Researchers retrospectively analyzed outcomes for 50 patients with biopsy-proven monoclonal gammopathy of renal significance for a median follow-up of 6.15 years.

Race, Geography Linked to Gaps in Prostate Cancer Care

A US government study finds racial disparities in care and a complicated relationship between distance to major cancer centers and patients’ treatment and outcomes.

PPI, Antibiotics May Curb Durvalumab Efficacy in NSCLC

Study adds to evidence that the widely used medications may interfere with immunotherapy efficacy via effects on the gut microbiome.

FDA Approves Subcutaneous Isatuximab for MM Indications

The drug can now be administered with the hands-free automated CirCLIQ on-body injector.

Recommended News For You

Best foot forward—chemo care should include podiatry, say researchers

Discovery reveals protein involved in Parkinson's disease also drives skin cancer

The lack of psychiatrists may be addressed by community workers.

Mezigdomide Combinations Show Promise in Multiple Myeloma

Watch for Psoriasis After Cancer Immunotherapy, Study Says

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

Testicular Mass Serendipitously Found 12 Years After Prostate Cancer Dx

Recommended Articles For You

A Clinical Review of Novel Therapeutics for Rare Cancers in the Genomics Era 

Beyond the Cure: The Emerging Role of Tissue-Agnostic Therapies in Palliative Oncology 

Unlocking the Potential of Hemin: A Novel Approach to Health and Wellbeing 

Everything You Need to Know About Normal Potassium Levels  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early-life exposure to air and light pollution linked to increased risk of pediatric thyroid cancer

2.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial

3.

Study finds 81% of cancer cures touted by TikTok videos are fake

4.

Loneliness and social isolation linked to heightened risk of death in those with cancer

5.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

1.

Senescence in Cancer Therapy: Mechanisms, Clinical Relevance, and Therapeutic Implications

2.

The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts

3.

Contemporary Frameworks in Oncology Across Clinical Settings

4.

Advanced Advances in Oncology for Healthcare Excellence

5.

Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

1.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

3.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

4.

Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias

5.

Thromboprophylaxis In Medical Settings

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot